Ebola Crisis Causes Drug Claim Symptoms In Products Marketed As Supplements
This article was originally published in The Pink Sheet Daily
Executive Summary
FTC joins FDA in one of the three warning letters to firms claiming their products can either prevent or treat Ebola.
You may also be interested in...
FDA Litigates To Wash Off Sanitizer Ebola Claim, Warns On Colloidal Silver Benefits
A complaint filed in federal court in California seeks an order to block Innovative BioDefense from distributing Zylast antiseptic hand sanitizer products that, due to its claims, are unapproved new drugs under FDA regulations. A warning letter to Silver Armor states that drug claims render its Silver Ramon and Natural Health brand products, which contain colloidal silver, unapproved new drugs and that the is noncompliant with supplement GMP regulations.
Flu Ushers In Risky Claims Season
Supplement firms are safest avoiding any mention of the flu, and trade groups see flu claims as a red flag for other problems. But flu season perennially brings in claims that skirt – or cross – the line, where they could draw fire from FDA.
FTC Stakes New Territory, Joins FDA In Warning On H1N1 Claims
A warning letter sent jointly by FDA and the Federal Trade Commission takes a double-pronged approach toward cracking down on a supplement marketer's claims regarding the H1N1 flu virus